LENZ Therapeutics’ (LENZ) “Buy” Rating Reiterated at HC Wainwright

LENZ Therapeutics (NASDAQ:LENZ)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $38.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 16.92% from the stock’s current price.

A number of other equities research analysts have also commented on LENZ. William Blair raised shares of LENZ Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Raymond James started coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They issued an “outperform” rating and a $37.00 price objective on the stock. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics presently has a consensus rating of “Buy” and an average price target of $35.40.

LENZ Therapeutics Stock Up 0.8 %

NASDAQ:LENZ traded up $0.27 during mid-day trading on Thursday, hitting $32.50. 264,169 shares of the company’s stock were exchanged, compared to its average volume of 135,853. The company has a 50 day simple moving average of $24.49 and a 200-day simple moving average of $20.99. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $36.50.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.09. On average, research analysts anticipate that LENZ Therapeutics will post -3.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. American International Group Inc. bought a new position in LENZ Therapeutics during the first quarter worth $44,000. SG Americas Securities LLC acquired a new position in LENZ Therapeutics during the third quarter worth $107,000. Squarepoint Ops LLC acquired a new position in LENZ Therapeutics during the second quarter worth $181,000. GSA Capital Partners LLP acquired a new position in LENZ Therapeutics during the third quarter worth $246,000. Finally, Rhumbline Advisers raised its holdings in LENZ Therapeutics by 265.6% during the second quarter. Rhumbline Advisers now owns 16,812 shares of the company’s stock worth $291,000 after buying an additional 12,214 shares during the last quarter. 54.32% of the stock is owned by institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.